Abstract
Introduction
Aortic valve disease (AVD) causes approximately 15,000 deaths per year in the United States, occurring in 2.8% of Americans over the age of 75 [1] . AVD is an active process driven by complex intercellular interactions [2] that is pathobiologically unique from other cardiovascular diseases [3] [4] [5] . Valve endothelial cells (VEC), which line the surface of the valve, are phenotypically different from other endothelial cell populations [6] [7] [8] [9] and must be investigated for unique pathological mechanisms. VEC are known to play a unique role in regulating the properties of valve tissue in response to the dynamic cardiac environment [10] [11] , but their role in early disease is not known. Disruption of VEC function is an early and persistent feature of AVD [12] [13] [14] , but it is not known if disrupted VEC actively contribute to valve calcification. Development of treatments that would protect against AVD by maintaining VEC protective function and blocking potential active contributions to calcification are hampered by a lack of understanding of the underlying mechanisms of VEC pathology.
VEC production of nitric oxide (NO) is protective against AVD, but is reduced in calcified valves [15] [16] [17] [18] . In vascular disease, NO is reduced due to a phenomenon known as eNOS uncoupling [19] , however, it is not known if eNOS uncoupling represents a significant source of oxidative stress in AVD. Uncoupled eNOS produces superoxide rather than nitric oxide due to a lack of the eNOS co-factor tetrahydrobiopterin (BH 4 ) [20] . Increased superoxide reacts with NO to form peroxynitrite (ONOO -), further reducing the bioavailability of NO [21] , or excess superoxide is dismutated to hydrogen peroxide (H 2 O 2 ) [22] . Superoxide and hydrogen peroxide are increased in calcifying regions of the aortic valve [23] [24] and contribute to osteogenic activation of valve interstitial cells [25] . If eNOS uncoupling is a significant phenomenon in the valve endothelium, VEC-derived oxidative stress could be an important and accessible target in the development of treatments to prevent valve calcification. Inflammation has long been clinically linked to oxidative stress [26] and eNOS uncoupling [27] in vascular endothelial cells, but it is not known whether a similar link exists in valve endothelial cells as a mechanism of valvular disease. Inflammatory activation of the endothelium correlates proportionally with calcification in AVD [28] . Inflammation induces early and sustained expression of endothelial inflammatory adhesion molecules VCAM-1 and ICAM-1 [29] . Inflammatory cytokine TNFα has been identified as a key effector of pro-inflammatory signaling in valve endothelial cells and of pro-calcific signaling in valve interstitial cells [30] [31] [32] . TNFα can also initiate a pro-disease endothelial to mesenchymal transition in adult VEC [33] [34] . However, it is not known if TNFα causes VEC to actively contribute pro-calcific oxidative stress to the diseased valve environment.
In this study, we establish that inflammatory cytokine TNFα drives increased oxidative stress in the valve endothelium, identifying valve endothelial cells as a novel source of elevated oxidative stress in AVD. We show that TNFα-driven endothelial oxidative stress, in part from eNOS uncoupling, causes endothelial dysfunction and exacerbates endothelial inflammatory response and that these effects can be prevented by treatment with TNFα+tetrahydrobiopterin (BH 4 ) or TNFα+peg-SOD. Results from our ex vivo AV leaflet culture show that blocking endothelial oxidative stress also mitigates TNFα-driven myofibroblastic activation, extracellular matrix remodeling, and calcification in the valve tissue. These findings identify a novel pathophysiological mechanism by which TNFα-driven endothelial oxidative stress initiates downstream calcification of the aortic valve. Antioxidant therapies that protect against endothelialderived increases in oxidative stress can mitigate valve disease progression by preserving the protective capabilities of the endothelium.
Methods

Human aortic valves
Calcified human aortic valves were obtained from adults undergoing planned, non-elective valve replacement surgery at Robert Packer Hospital in Sayre, PA. The Guthrie Institutional Review Board at Robert Packer Hospital and the Institutional Review Board for Human Participants at Cornell University approved all procedures (IRB#0908-24, "Gene expression and phenotypic changes in stenotic aortic valves"). Written informed consent was obtained from all participants. The investigation conformed to the principles outlined in the Declaration of Helsinki. Patient age range was 65-90 years, with a mean age of 76.2 years, 21 samples total. Dihydroethidium (DHE) superoxide detection and immunofluorescence were performed as described in the S1 Supplement.
Aortic valve endothelial cells
Valve endothelial cells (VEC) were harvested from porcine aortic valves (Shirk Meats, Dundee, NY). Use of porcine cells, a widely-accepted human valve analog, provided a large, controlled population of VEC that were screened for phenotype and purity using q-rtPCR and immunofluorescence for CD31, eNOS, VE-cadherin, and absence of αSMA (see S1 Supplement). VEC were found to maintain their endothelial phenotype and purity out to passage six, thus all experiments were conducted between P4 and P6. In all in vitro experiments, VEC were cultured at 100,000 cells/cm 2 on 3-D collagen hydrogels recapitulating the native valve environment, as described previously [35] .
Endothelial oxidative stress state assessment
Human recombinant TNFα was administered at dosages from 10-100ng/mL and determined to have a significant inflammatory effect (VCAM-1 upregulation, NFκB nuclear translocation) with no statistically significant VEC apoptosis at 30ng/mL, as previously shown [33] . H 2 O 2 dosage (1 μmol/L) was chosen to recapitulate peak increases in secreted H 2 O 2 by VEC stimulated with 30ng/mL TNFα. Acute increases in oxidative stress due to TNFα were measured across 0-4 hours. Peak effect occurred and is presented here at 30 minutes post-treatment. Intracellular oxidative stress was assessed via DHE fluorescence and CM-H2DCF-DA fluorescence, quantified on a microplate reader and with confocal microscopy. Secreted NO was measured using the Griess assay. Secreted H 2 O 2 was measured by the Fluoro H 2 O 2 assay. Mitochondrial reactive oxygen species were measured using MitoSOX Red assay, quantified on a microplate reader and with confocal microscopy. Efficacy of antioxidant administration was optimized for pre-treatment time and dosage. Peak effect was achieved by administering 500μmol/L L-NAME 30 minutes prior to TNFα treatment and all other co-treatments concurrently with TNFα, using 10 μmol/L BH 4 , 100 μmol/L apocynin (acetovanillone), and 20U/mL Cu-Zn-Superoxide dismutase-polyethylene glycol (peg-SOD).
Ex vivo aortic valve leaflets
Porcine aortic valve leaflets were harvested sterilely from fresh porcine hearts (Shirk Meats, Dundee, NY). Leaflets were immediately rinsed in sterile PBS, transported on ice, and transferred to Dulbecco's Modified Eagle Medium within two hours. D-MEM was supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, adjusted to a pH of 7.2. 30ng/mL of TNFα was added directly to the media, supplemented with 10 μmol/L BH 4 or 20U/mL peg-SOD, where noted. This culture media was changed every 48 hours for 21 days. TUNEL assay for apoptosis was performed to confirm cell viability and DHE or MitoSOX Red assay were used to detect oxidative stress. Russell-Movat pentachrome staining was used to visualize extracellular matrix components and Alizarin Red S in combination with von Kossa staining was used to assess calcification. Western blot, mRNA isolation, q-rtPCR, and immunofluorescence were performed according to standard practices, as described in the S1 Supplement.
Statistical Analysis
Data is expressed as mean +/-standard error of the mean (SEM). All comparisons between two groups were made using two-tailed, unpaired t-tests assuming unequal variance. Comparisons between multiple groups were made using one-way ANOVA with Tukey's post hoc tests. Differences between means were considered significant when p < 0.05.
Results
Calcified human aortic valves show elevated endothelial superoxide in a side specific manner, co-localized with inflammatory activation
We first examined superoxide levels in calcified (cHAV) human aortic valves, using DHE intensity. Superoxide levels were significantly increased in calcified regions of the valves ( Fig 1A) and in the fibrosa endothelium, but not in non-calcified regions or the ventricularis endothelium ( Fig 1A and 1B) . Elevated endothelial superoxide was associated with the fibrosa side of the stenotic human aortic valve, where calcific lesions are known to form. Across cHAV samples, regions of the endothelium with high levels of superoxide were positive for both VCAM-1 and CD31 (Fig 1C) , indicating a link between inflammatory endothelial activation and elevated endothelial superoxide. The interstitial cells directly beneath the human VEC (hVEC) did not have significantly increased superoxide (arrows). hVEC on the ventricularis side were positive for CD31, but did not have significantly increased superoxide or elevated VCAM-1 expression ( Fig 1C) .
Side-specific expression of endothelial superoxide dismutase in calcified human aortic valves
The fibrosa endothelium of diseased valves showed little to no SOD1 expression, while the ventricularis endothelium retained strong expression of SOD1 (Fig 2A) . Quantitative analysis of SOD1 expression in the CD31 + endothelial cells of cHAV confirmed that the fibrosa endothelium showed significantly less SOD1 than the ventricularis endothelium ( Fig 2B) .
TNFα causes increased oxidative stress and decreased NO in VEC
TNFα caused a significant increase in VEC intracellular oxidative stress (Fig 3A) , superoxide (S1 Fig 3C) and decreased expression of eNOS and VE-cadherin proteins ( Fig 3D and S2 Fig) .
To elucidate the source of increases in endothelial oxidative stress and the resulting endothelial dysfunction, we administered NOS inhibitor L-NAME, eNOS co-factor BH 4 , NADPH oxidases inhibitor apocynin, or peg-SOD in conjunction with TNFα treatment. At 30 minutes, L-NAME, BH 4 , and peg-SOD blocked TNFα-stimulated increases in VEC superoxide, but apocynin did not (Fig 3E) . L-NAME and apocynin reduced overall oxidative stress compared to TNFα alone, and peg-SOD lowered oxidative stress further still. Only eNOS co-factor BH 4 restored VEC oxidative stress back to control levels ( Fig 3F) . Similar trends were observed in H 2 O 2 secretion: co-administration of L-NAME, BH 4 , or peg-SOD blocked increases in secreted H 2 O 2 by VEC, but apocynin did not (Fig 3G) . TNFα similarly drove increases in VEC mitochondrial reactive oxygen species (mtROS), which were only abrogated by peg-SOD ( Fig 3H) . Over 48 hours, only BH 4 or peg-SOD maintained control levels of nitric oxide secretion ( Fig 3I) . Catalase co-treatment was able to reduce general oxidative stress state in VEC, but was found to cause a significant increase in apoptosis, loss of VE-cadherin, nuclear translocation of NFκB, and VCAM-1 expression (S3 Fig) . Thus, catalase treatment had off-target effects on VEC that were significant enough to prevent further investigation of its viability as a pro-endothelial valve treatment against inflammation and calcification.
Mitigating the effects of TNFα-oxidative stress rescues endothelial function and abates VEC inflammatory response
We then examined the protein-level effects of BH 4 and peg-SOD on VEC when applied in conjunction with TNFα treatment. TNFα decreased VE-cadherin and eNOS and increased VCAM-1 protein expression in VEC (Fig 4A, arrows) . Co-treatment of VEC with BH 4 or peg-SOD protected against loss of VE-cadherin and eNOS and reduced VCAM-1 response to TNFα. Western blot analysis confirmed this result (Fig 4B and 4C and S4 Fig) .
TNFα increases VEC oxidative stress in ex vivo aortic valve leaflets, rescued by antioxidants
We then used ex vivo culture of healthy porcine AV leaflets to examine tissue-level effects of TNFα-driven endothelial oxidative stress and the ability of BH 4 or peg-SOD to mitigate TNFα effects. No significant apoptosis was observed in the leaflets throughout the course of the experiment (S5 Fig) . Similar to our findings in vitro, over 21 days TNFα increased endothelial superoxide, most distinctly in the fibrosa endothelium (Fig 5A) . BH 4 treatment mitigated fibrosa but not ventricularis-side increases in superoxide. Peg-SOD lowered endothelial superoxide even further than BH 4 , significantly decreasing levels on both the fibrosa and ventricularis sides ( Fig  5B) . To elucidate a potential mechanism behind differential BH 4 and peg-SOD effects, we examined the contribution of mitochondrial reactive oxygen species (mtROS) within our ex vivo leaflets. We found that TNFα indeed increased levels of mtROS, specifically within the ventricularis endothelium (Fig 5C) . Quantification of mtROS fluorescence revealed a 42±9.3% increase in mtROS only in ventricularis VEC and not in fibrosa VEC or VIC, which was mitigated by co-treatment with SOD, but not BH 4 ( Fig 5D) . Antioxidants improve endothelial function and repress valve interstitial cell myofibroblastic activation in aortic valve leaflets AV leaflets cultured in TNFα for 21 days showed significant endothelial dysfunction, with decreases in CD31, VE-cadherin, and eNOS on both the fibrosa and the ventricularis. These effects were rescued by co-treatment with BH 4 or peg-SOD. TNFα also caused upregulation of VCAM-1 on both sides of the valve, which was mitigated almost entirely on both the fibrosa and ventricularis by co-treatment with BH 4 or peg-SOD. TNFα significantly increased αSMA in both the endothelium and the underlying interstitium on both sides of the valve, decreased on the fibrosa by peg-SOD and on the ventricularis by BH 4 or peg-SOD (Fig 6A) . Loss of VEcadherin and eNOS and increases in αSMA due to TNFα and the protective effect of antioxidants were confirmed via western blot analysis (Fig 6B and S6 Fig) .
TNFα causes extracellular matrix disorganization and calcification in aortic valve leaflets, rescued by antioxidants Ex vivo aortic valve leaflets treated with TNFα for 21 days showed significant fibrogenesis and osteogenesis compared to controls. Control AV leaflets showed distinct trilaminar structure of the extracellular matrix (ECM), with well-defined organization of elastin fibers within the ventricularis (arrow, Fig 7A) . Valve leaflets treated with TNFα showed ECM disorganization, marked by significantly decreased elastin and glycosaminoglycans (GAG), and significantly increased collagen. q-rtPCR analysis of the valve tissue showed increased synthesis of COL1A1 and COL3A1 mRNA with TNFα (Fig 7B) . BH 4 protected against loss of elastin and GAG, but A, In ex vivo porcine aortic valve leaflets, TNFα decreased endothelial proteins CD31, VE-cadherin, and eNOS on both sides of the valve, rescued by BH 4 or peg-SOD. TNFα increased VCAM1 on both sides of the valve, mitigated by BH 4 or peg-SOD. TNFα increased αSMA on both sides of the valve, which was mitigated on the fibrosa by peg-SOD but not by BH 4 (arrow) and on the ventricularis by either BH 4 or SOD. B, Western blot quantification confirmed loss of VE-cadherin and eNOS and increase in αSMA in TNFα condition that is rescued by BH 4 or peg-SOD. * indicates p < 0.05 versus CTL, # indicates p < 0.05 versus TNFα. Scale bar = 20μm. N = 6. doi:10.1371/journal.pone.0123257.g006
Endothelial Oxidative Stress in AV Calcification allowed similar increases in collagen as in TNFα alone. Peg-SOD protected against loss of elastin and GAG and provided significant protection against increases in collagen, maintaining collagen expression at control levels. Peg-SOD blocked increases in COL1A1 and COL3A1 mRNA. COL2A1 was decreased in all treatment conditions. Alizarin red staining showed significant increase in free calcium in leaflets cultured with TNFα, localized to the fibrosa side of the leaflets (Fig 7C, arrows) that was mitigated by BH 4 and returned to control levels by peg-SOD. von Kossa staining showed an increase in mineralization, again on the fibrosa, in leaflets cultured with TNFα that was equally blocked by BH 4 or peg-SOD (Fig 7D) . BH 4 caused minimal off-target effects on a range of markers regulating AV function (S7 Fig) .
TNFα increased synthesis of mRNA for alkaline phosphatase, an enzyme involved in active bone formation, which was mitigated by co-treatment with BH 4 or peg-SOD. TNFα decreased synthesis of mRNA for the anti-osteogenic transcription factor Sox9, indicating a pro-calcific phenotypic shift that was rescued by co-treatment with BH 4 . TNFα also increased synthesis of mRNA for matrix metalloproteinase-9, mitigated by BH 4 or peg-SOD (Fig 7E) .
Discussion
Aortic valve disease is a pressing medical issue with few clinically useful pharmacological intervention strategies. New therapies are needed that target specific cellular mechanisms that will guard against valve degeneration. In this study, we have shown the valve endothelium to be a novel source of oxidative stress in the aortic valve when stimulated with the inflammatory cytokine TNFα (Fig 8) . We further showed that targeting this mechanism via antioxidants directed at superoxide levels protects against loss of endothelial function, chronic inflammation response, myofibroblastic activation, calcification, and extracellular matrix disorganization.
We showed that regions of the calcified valve endothelium with high VCAM-1 co-localized with regions of high superoxide, linking inflammation with oxidative stress in the diseased valve endothelium. This phenomenon occurs in both mildly and heavily affected regions of the valve, specifically on the fibrosa side of the leaflet. This pervasive and side-specific co-localization of inflammatory activation and oxidative stress in the endothelium suggests that TNFα-driven endothelial oxidative stress occurs throughout mild and advanced stages of AVD. Side-specificity of endothelial oxidative stress points to a distinct involvement of this endothelial-specific mechanism with calcific lesion formation, known to develop preferentially on the fibrosa [36] . Our observation of increased superoxide levels in hVEC but not the adjacent hVIC supports a role for valve endothelial cells as a unique source of oxidative stress in the diseased valve, distinct from oxidative stress previously described in the calcifying regions of the valve [23] [24] or as a result of immune cell invasion. We also observed fibrosa-specific loss of SOD1 expression in cHAV, indicating a dearth of SOD1 in the diseased fibrosa endothelium during CAVD, making the valve more susceptible to increases in oxidative stress from the endothelium. Low fibrosa SOD1 compared to the ventricularis in cHAV can also explain the TNFα induces early calcification and changes in aortic valve extracellular matrix composition and structure, rescued differentially by BH 4 or peg-SOD. A, TNFα increased collagen and decreased GAG and elastin (arrows). BH 4 maintains GAG and elastin at control levels, but does not block increases in collagen. Peg-SOD significantly reduced collagen compared to TNFα and maintained control levels of GAG and elastin (Blue: glycosaminoglycans, Red: mucins, Yellow: collagen, Black, elastin). B. TNFα increased synthesis of COL1A1 and COL3A1 mRNA, rescued by peg-SOD but not by BH 4 . COL2A1 was decreased in all treatment conditions. * indicates p < 0.05 versus control, # indicates p < 0.05 versus TNFα. N = 6. One-way ANOVA with Tukey's post hoc test were used to compare means. C, TNFα increased calcium deposition (Alizarin Red S stain) that is rescued by BH 4 or peg-SOD. D, TNFα increased mineralization (von Kossa stain), rescued by BH 4 or peg-SOD. E, TNFα increased alkaline phosphatase, decreased Sox9, and increased MMP-9 mRNA, rescued differentially by BH 4 Recently, TNFα signaling has been implicated as a key inflammatory pathway in stenotic aortic valves [37] [38] [39] . Mouse models of hypercholesterolemia show inflammatory activation of the endothelium, increased superoxide [40] , and endothelial dysfunction [41] . Here, we have demonstrated that TNFα increases endothelial oxidative stress, decreases NO secretion, and lowers VE-cadherin and eNOS protein expression in valve endothelial cells, both in vitro and ex vivo. This finding provides a mechanistic link between inflammation, endothelial dysfunction, and oxidative stress. TNFα-derived oxidative stress effects were blocked by co-treatment with eNOS co-factor BH 4 , demonstrating that eNOS uncoupling is a primary mechanism of increased endothelial oxidative stress and a significant cause of endothelial dysfunction that leads to increased AV calcification via degradation of endothelial protection.
Co-treatment of VEC with TNFα+catalase did not protect the endothelium, but led to increased cellular apoptosis and elevated inflammatory activation. This agrees with previous studies that have shown that in certain cell types, H 2 O 2 actually protects against TNFα -induced apoptosis and that increased levels of catalase has a neutral or negative effect [42] [43] [44] . The ability of apocynin to mitigate TNFα-driven endothelial oxidative stress levels as indicated by DCF staining shows that NADPH oxidases also have a role to play in this phenomenon, though it appears to be less important than the uncoupling mechanism, as demonstrated by the more potent effects of BH 4 . These findings define two unique mechanisms of endothelial oxidative stress contribution to AVD: via changes in eNOS activity due to uncoupling and disruption of native SOD1 and H 2 O 2 levels. TNFα driven oxidative stress, in part due to eNOS uncoupling, degrades the endothelial protection that would normally mitigate valve Endothelial Oxidative Stress in AV Calcification degeneration [15, 17] and increases oxidative stress in the valve. This establishes a novel mechanism of valve oxidative stress based on endothelial inflammatory activation, distinct from existing descriptions of oxidative stress that have focused on valve interstitial cells [25, [45] [46] [47] .
We further established the ability of BH 4 and peg-SOD to mitigate increases in VCAM-1 that occurred in VEC in response to TNFα. This dovetails with recent studies that implicate side-specific VCAM-1 expression in the progression and regulation of AVD [48] [49] . Thus, mitigating the cellular stress imposed on VEC by TNFα-driven eNOS uncoupling may also decrease the need to activate downstream inflammatory signaling pathways. Mitigation of the symptoms of chronic inflammation could prove important to aortic valve calcification, as the TNFα signaling pathway is known to promote osteogenesis [50] and to be an active regulator of lesion formation in the vasculature [51] . Translation of our cellular-level findings into an ex vivo evaluation of AV leaflets allowed us to assess the specific effects of TNFα and antioxidants on the complex, multicellular aortic valve leaflet. We found that superoxide levels in TNFα-treated valve leaflets was specifically elevated in VEC, with highest elevation on the fibrosa side, confirming that endothelial superoxide in cHAV is linked to inflammation of the valve endothelium. Interestingly, co-treatment of ex vivo AV leaflets with TNFα+BH 4 reduced oxidative stress only in the fibrosa endothelium compared to TNFα alone, whereas peg-SOD reduced oxidative stress on both sides of the valve leaflet. Examination of mitochondrial ROS provided an explanation for this difference, as peg-SOD but not BH 4 lowered mtROS levels within the ventricularis of ex vivo leaflets. We conclude that BH 4 treatment mitigates valve oxidative stress via direct targeting of fibrosa-specific eNOS uncoupling, whereas peg-SOD mitigates both fibrosa-specific eNOS uncoupling and mtROS within ventricularis VEC. A limitation of this study is the lack of direct experimental interrogation of mtROS as a propagator of AVD; however, the evidence presented here provides a foundation for future investigation of mitochondrial contribution to increased oxidative stress in the aortic valve in the early inflammatory stages of AVD.
Immunofluorescent staining confirmed the side-specific effect of BH 4 . CD31, VE-cadherin, and eNOS were more robustly restored on the fibrosa with co-treatment of TNFα+BH 4 , compared to TNFα alone. TNFα caused increased αSMA in the fibrosa, potentially due to mesenchymal transition of valve endothelial cells [34] , in addition to direct myofibroblastic activation of valvular interstitial cells [31] . TNFα-induced increases in αSMA were blocked by co-treatment of valve leaflets with TNFα+BH 4 or TNFα+peg-SOD, demonstrating a role for both eNOS uncoupling and superoxide from other sources such as NADPH oxidases and mtROS in driving myofibroblastic activation during AVD.
TNFα exposure caused significant disruption of the extracellular matrix organization and content of the aortic valve. TNFα increased collagen and decreased GAG and elastin, agreeing with studies that find differential GAG localization [52] and reduced elastin [53] in diseased aortic valves. GAG and elastin were preserved by BH 4 or peg-SOD. Increases in collagen were only mitigated by peg-SOD, not by BH 4 . mRNA analysis showed that increased collagen was caused by increased expression of COL1A1 and COL3A1 isoforms in TNFα and TNFα+BH 4 conditions, but rescued in TNFα+peg-SOD condition. Interestingly, COL2A1 was uniformly decreased across TNFα, TNFα+BH 4 , and TNFα+peg-SOD conditions, pointing to TNFα as a driver of early chondrocyte differentiation in valve cells and as an important contributor to valve calcification via a mechanism separate from the oxidative stress pathways examined here [54] . These findings indicate that protection against excess valve endothelial oxidative stress can guard against ECM changes known to feature in AVD [55] via antioxidant mitigation of inflammation, endothelial dysfunction, and oxidative stress.
TNFα accelerates calcification of aortic valve interstitial cells in vitro [32] [33] . However, the contribution of TNFα to AVD within the complex multi-cellular environment of the native aortic valve is unknown. Here we used TNFα with and without BH 4 treatment to show that stimulation of endothelial eNOS uncoupling by TNFα contributes to valve calcification, elucidating a novel mechanism of TNFα contribution to AVD. Increases in alkaline phosphatase point to the mechanism behind these changes, indicating that TNFα stimulates early osteogenic differentiation of valve interstitial cells, as has been observed in vitro under TGF-β stimulation [56] , that can be protected against by preservation of endothelial function and reductions in oxidative stress.
Antioxidant therapy for AVD must be founded on specific mechanisms generating oxidative stress in order to be efficacious [57] . The evidence presented here establishes inflammatory activation of endothelial oxidative stress as a unique integrated pathobiological mechanism effecting early to late stages of aortic valve disease. Our findings support that specific targeting of eNOS uncoupling and the resulting excess superoxide may be key elements of managing AVD via antioxidant treatments.
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